Drug Markets/BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE

BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE

3 NDCs across 1 manufacturers|0 Generic,3 Brand

Total NDCs

0G / 3B

Manufacturers

competing in market

Price Spread

$136.69 – $136.73

Up to 0% savings

7d Activity

9↓-6 flat

of 3 total NDCs

Monthly average NADAC price per unit, split by generic and brand

1 manufacturer producing BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE

3 NDCs total, 3 shown

Drug ↕	NDC	Manufacturer ↕	Price	Market Outlier	Class	7d Change ↕	Therapeutic Class
BIKTARVY 50-200-25 MG TABLET	61958250101	Gilead Sciences, Inc.	$136.7317 per EA	—	Brand	-0.01%	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor, Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor, Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
BIKTARVY 50-200-25 MG TABLET	61958250103	Gilead Sciences, Inc.	$136.7317 per EA	—	Brand	-0.01%	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor, Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor, Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
BIKTARVY 30-120-15 MG TABLET	61958250501	Gilead Sciences, Inc.	$136.6925 per EA	—	Brand	-0.03%	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor, Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor, Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor